SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy
(SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for
the treatment of metastatic kidney cancer.